Coeur Mining or First Majestic: Which Miner Offers Better Value? — Positive
AG CDE Zacks Investment Research — December 30, 2025CDE and AG are benefiting from higher gold and silver prices as strong Q3 production, rising cash flow and balance sheet gains fuel momentum.
KLAR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Klarna Group plc — Neutral
KLAR Newsfile Corp — December 30, 2025Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Klarna To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Klarna pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Registration Statement") issued in connection with Klarna's September 2025 initial public offering (the "IPO") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 30, 2025) - Faruqi …
DraftKings Adds Spanish-Language App: Unlocking a New Growth Channel? — Positive
DKNG Zacks Investment Research — December 30, 2025DKNG plans a Spanish-language app ahead of the 2026 World Cup, targeting Hispanic bettors to drive acquisition, engagement and long-term growth.
2 Instruments Stocks Likely to Benefit From Industrial Digitization — Positive
ST THR Zacks Investment Research — December 30, 2025The increasing adoption of industrial automation, focus on higher energy efficiency and optimum resource utilization should drive the Zacks Instruments - Control industry. ST and THR are well-positioned to gain from the evolving market dynamics.
IVZ Among Top-Performing S&P 500 Asset Managers in 2025: Is It a Buy? — Positive
IVZ Zacks Investment Research — December 30, 2025Invesco soars 53.5% in 2025, topping S&P 500 asset managers. However, muted revenue growth and high intangibles raise buy-or-wait questions.
My New Year's Resolution For 2026: Invest $10,000 In These 5 Stocks — Positive
CME CVX DVN EOG EQNR FDS KO LDNXF LSEGY MTDR PG PR XOM Seeking Alpha — December 30, 2025Dividend growth investing is not a get-rich-quick strategy, it requires commitment and a long-term mindset. Making a New Year's resolution is a great way to help maintain that mindset. I reflect on 2025 and review five companies that I am convinced will bring me closer to my goal of being able to fund my living expenses through dividends. The companies I review in this article should do well in an environment characterized by ongoing fiscal dominance and long-term higher inflation.
MongoDB: Following Palantir's Playbook (Rating Upgrade) — Positive
MDB Seeking Alpha — December 30, 2025I am upgrading MongoDB, Inc. to a Buy after two consecutive quarters of 800 bps revenue beats and significant margin expansion coupled with impressive raise to forward guidance. MDB's Atlas platform accelerated growth to 30% YoY, now 75% of revenue as it positions itself as an indispensable layer in the AI infrastructure stack. MongoDB is also following a similar playbook like Palantir, with its product strategy and magnitude of revenue and earnings beats and forward raises.
Silver will see more volatility, but the market is not in a bubble - Société Générale — Neutral
SIL SILJ SIVR SLV SLVP Kitco — December 30, 2025Neils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada.
BLDP vs. BE: Which Hydrogen Power Stock Has Better Potential for 2026? — Positive
BE BLDP Zacks Investment Research — December 30, 2025Bloom Energy's strong ROIC, faster earnings growth and surging stock performance give it an edge over Ballard Power.
MVST vs. PATH: Which Growth Tech Stock Belongs in Your Portfolio? — Positive
MVST PATH Zacks Investment Research — December 30, 2025UiPath's AI-driven automation momentum, strong cash position and enterprise adoption stand out against Microvast's growth, losses and liquidity strain.
Can CoreWeave Maintain More Than 60% EBITDA Margins Amid Rising CapEx? — Positive
CRWV Zacks Investment Research — December 30, 2025CRWV posts Q3 2025 adjusted EBITDA of $838M with margins above 60%, citing AI-optimized infrastructure, contracted demand and a resilient outlook.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sprouts Farmers Market — Neutral
SFM Newsfile Corp — December 30, 2025Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Sprouts to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Sprouts between June 4, 2025 and October 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - December 30, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sprouts Farmers Market, Inc. …
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Firefly Aerospace — Neutral
FLY Newsfile Corp — December 30, 2025Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Firefly Aerospace To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired: (a) Firefly common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about August 7, 2025 (the "IPO" or "Offering"); and/or (b) Firefly securities between August 7, 2025 and September 29, 2025, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at …
Pool Corp: Why is this Warren Buffett-backed stock down 53%? — Negative
POOL Invezz — December 30, 2025Pool Corp's stock price has been in a strong freefall this year, and is now at its lowest level since 2020. It has plunged by ~53% from its highest point this year, erasing $16 billion in value as the market capitalization dropped from $24.5 billion to the current $8 billion.
RBLX vs TTWO: Which Gaming Stock Has the Stronger 2026 Setup? — Positive
RBLX TTWO Zacks Investment Research — December 30, 2025Roblox and Take-Two head into 2026 with sharply different models, pitting platform-driven growth against franchise-led earnings visibility.
Can DIS Stock Maintain Momentum With Streaming Wins and Parks Growth? — Positive
DIS Zacks Investment Research — December 30, 2025DIS gains traction as streaming turns profitable and parks post record income, setting up a pivotal test of whether Disney can sustain growth momentum.
Seeking Income Into 2026? 3 High-Yield Stocks to Buy Now — Positive
AES PAGP TEF Zacks Investment Research — December 30, 2025Amid uncertainty and easing interest rates, investors seeking high-yield income can consider dividend stocks such as PAGP, AES and TEF.
Best Momentum Stock to Buy for December 30th — Positive
IVR RIO VALE Zacks Investment Research — December 30, 2025RIO, IVR and VALE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2025.
Polaris: Buy This Dividend Aristocrat As Turnaround Continues — Positive
PII Seeking Alpha — December 30, 2025Polaris is rebounding from cyclical headwinds, showing strong revenue growth and market share gains in core segments. PII is streamlining operations, selling a majority stake in Indian Motorcycle to focus on higher-margin Off-Road, Snow, Marine, and Slingshot businesses. Dealer inventory is down 21% YoY, with aged inventory reduced over 60%, supporting working capital and positioning for normalized demand.
TG Therapeutics: What Wall Street Isn't Telling You — Positive
TGTX Seeking Alpha — December 30, 2025TG Therapeutics, Inc. is my favorite in the multiple sclerosis therapeutics market. In my opinion, it's Briumvi that has the best efficacy among anti-CD20 monoclonal antibodies, including Ocrevus and Kesimpta. Thanks to the increased demand for Briumvi, TG Therapeutics' EBIT margin increased by 3% year-on-year to 18.2%.